Molecular basis for nonspecificity of nonsteroidal anti-inflammatory drugs (NSAIDs)
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“small molecule drugs in particular tend to bind a myriad of molecular targets (120)”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural Basis of the Drug-binding Specificity of Human Serum Albumin
Ghuman, J., Zunszain, P. A., Petitpas, I., Bhattacharya, A. A., Otagiri, M., & Curry, S. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.075 · Cited by 1,941
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110
Prophylactic Use of NSAIDs by Athletes: A Risk/Benefit Assessment
Warden, S. J. (2010) · The Physician and Sportsmedicine · doi:10.3810/psm.2010.04.1770 · Cited by 144
Pathi, S., Jutooru, I., Chadalapaka, G., Nair, V., Lee, S.-O., & Safe, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048208 · Cited by 127
Research works printed but not linked: 98
- Vane, 1976, The mode of action of aspirin and similar compounds, J. Allergy Clin. Immunol., 58, 691, 10.1016/0091-6749(76)90181-0 · DOI · Paper page
- Vane, 2000, The fight against rheumatism: from willow bark to COX-1 sparing drugs, J. Physiol. Pharmacol., 51, 573
- Green, 2001, Understanding NSAIDs: from aspirin to COX-2, Clin. Cornerstone, 3, 50, 10.1016/S1098-3597(01)90069-9 · DOI · Paper page
- Allaj, 2013, Non-steroid anti-inflammatory drugs, prostaglandins, and cancer, Cell Biosci., 3, 8, 10.1186/2045-3701-3-8 · DOI
- Wallace, 2008, Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself?, Physiol. Rev., 88, 1547, 10.1152/physrev.00004.2008 · DOI · Paper page
- Wallace, 2013, Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy, World J. Gastroenterol., 19, 1861, 10.3748/wjg.v19.i12.1861 · DOI · Paper page
- Lanas, 1992, Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding, Gastroenterology, 103, 862, 10.1016/0016-5085(92)90018-T · DOI · Paper page
- McCarthy, 2009, GI bleeding: problems that persist, Gastrointest. Endosc., 70, 225, 10.1016/j.gie.2008.12.247 · DOI
- Stack, 2002, Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding, Aliment. Pharmacol. Ther., 16, 497, 10.1046/j.1365-2036.2002.01197.x · DOI · Paper page
- Hawkey, 1996, Non-steroidal anti-inflammatory drug gastropathy: causes and treatment, Scand. J. Gastroenterol. Suppl., 220, 124, 10.3109/00365529609094763 · doi:10.3109/00365529609094763
- Makris, 2010, Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review, J. Rheumatol., 37, 1236, 10.3899/jrheum.090935 · DOI
- McGettigan, 2013, Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries, PLoS Med., 10, e1001388, 10.1371/journal.pmed.1001388 · DOI · Paper page
- Scarpignato, 2013, Piroxicam-β-cyclodextrin: a GI safer piroxicam, Curr. Med. Chem., 20, 2415, 10.2174/09298673113209990115 · DOI
- Shau, 2012, Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence, BMC Cardiovasc. Disord., 12, 4, 10.1186/1471-2261-12-4 · DOI
- Sinha, 2013, Current perspectives in NSAID-induced gastropathy, Mediat. Inflamm., 2013, 258209, 10.1155/2013/258209 · DOI
- Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. D: Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
- DeLano, 2005, The case for open-source software in drug discovery, Drug Discov. Today, 10, 213, 10.1016/S1359-6446(04)03363-X · DOI
- Collaborative Computational Project, Number 4, 1994, The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D: Biol. Crystallogr., 50, 760, 10.1107/S0907444994003112 · DOI · Paper page
- Chandrasekharan, 2002, COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, Proc. Natl. Acad. Sci. U. S. A., 99, 13926, 10.1073/pnas.162468699 · DOI · Paper page
- Gudis, 2005, The role of cyclooxygenase in gastric mucosal protection, Dig. Dis. Sci., 50, 16, 10.1007/s10620-005-2802-7 · DOI
- Simopoulos, 2002, Omega-3 fatty acids in inflammation and autoimmune diseases, J. Am. Coll. Nutr., 21, 495, 10.1080/07315724.2002.10719248 · DOI · Paper page
- Boursinos, 2009, Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing?, J. Musculoskelet. Neuronal Interact., 9, 44
- Hennan, 2001, Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries, Circulation, 104, 820, 10.1161/hc3301.092790 · DOI · Paper page
- Mattia, 2005, COX-2 inhibitors: pharmacological data and adverse effects, Minerva Anestesiol., 71, 461
- McGeer, 2001, Cardiovascular events and COX-2 inhibitors, JAMA, 286, 2810
- Patrignani, 2008, Risk management profile of etoricoxib: an example of personalized medicine, Ther. Clin. Risk Manag., 4, 983, 10.2147/TCRM.S3209 · DOI
- Picot, 1994, The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1, Nature, 367, 243, 10.1038/367243a0 · DOI · Paper page
- Rimon, 2010, Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1, Proc. Natl. Acad. Sci. U. S. A., 107, 28, 10.1073/pnas.0909765106 · DOI · Paper page
- Loll, 2001, O-acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H2 synthase: structural and functional characterization of enzyme–inhibitor interactions, Mol. Pharmacol., 60, 1407, 10.1124/mol.60.6.1407 · doi:10.1124/mol.60.6.1407
- Selinsky, 2001, Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations, Biochemistry, 40, 5172, 10.1021/bi010045s · DOI · Paper page
- Sidhu, 2010, Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers, Biochemistry, 49, 7069, 10.1021/bi1003298 · DOI · Paper page
- Kurumbail, 1996, Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature, 384, 644, 10.1038/384644a0 · DOI · Paper page
- Duggan, 2010, Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen, J. Biol. Chem., 285, 34950, 10.1074/jbc.M110.162982 · DOI · Paper page
- Rowlinson, 2003, A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385, J. Biol. Chem., 278, 45763, 10.1074/jbc.M305481200 · DOI · Paper page
- Wang, 2010, The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life, Bioorg. Med. Chem. Lett., 20, 7159, 10.1016/j.bmcl.2010.07.054 · DOI · Paper page
- Tacconelli, 2002, The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity, Curr. Med. Res. Opin., 18, 503, 10.1185/030079902125001335 · DOI
- Singh, 2004, Phospholipase A2 as a target protein for nonsteroidal anti-inflammatory drugs (NSAIDS): crystal structure of the complex formed between phospholipase A2 and oxyphenbutazone at 1.6Å resolution, Biochemistry, 43, 14577, 10.1021/bi0483561 · doi:10.1021/bi0483561
- Singh, 2009, Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4Å resolution reveals the presence of the new common ligand-binding site, J. Mol. Recognit., 22, 437, 10.1002/jmr.960 · doi:10.1002/jmr.960
- Singh, 2005, Aspirin induces its anti-inflammatory effects through its specific binding to phospholipase A2: crystal structure of the complex formed between phospholipase A2 and aspirin at 1.9 angstroms resolution, J. Drug Target., 13, 113, 10.1080/10611860400024078 · doi:10.1080/10611860400024078
- Singh, 2006, Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7Å resolution, Acta Crystallogr. D: Biol. Crystallogr., 62, 410, 10.1107/S0907444906003660 · DOI
- Kaplan, 1978, Low concentrations of indomethacin inhibit phospholipase A2 of rabbit polymorphonuclear leukocytes, Proc. Natl. Acad. Sci. U. S. A., 75, 2955, 10.1073/pnas.75.6.2955 · DOI
- Wu, 2008, Structural basis for catalytic and inhibitory mechanisms of human prostaglandin reductase PTGR2, Structure, 16, 1714, 10.1016/j.str.2008.09.007 · DOI
- Lovering, 2004, Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin, Cancer Res., 64, 1802, 10.1158/0008-5472.CAN-03-2847 · DOI · Paper page
- Watanabe, 1992, Relation between cytochrome P-450 increase and endoplasmic reticulum proliferation in hepatocytes of mice treated with phenobarbital: a microphotometric and morphometric study, J. Histochem. Cytochem., 40, 353, 10.1177/40.3.1552174 · doi:10.1177/40.3.1552174
- Guengerich, 2008, Cytochrome p450 and chemical toxicology, Chem. Res. Toxicol., 21, 70, 10.1021/tx700079z · DOI · Paper page
- Degtyarenko, 1995, Structural domains of P450-containing monooxygenase systems, Protein Eng., 8, 737, 10.1093/protein/8.8.737 · doi:10.1093/protein/8.8.737
- Wester, 2004, The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution, J. Biol. Chem., 279, 35630, 10.1074/jbc.M405427200 · DOI · Paper page
- Zhu, 2012, Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine, J. Pharmacol. Exp. Ther., 343, 362, 10.1124/jpet.112.198077 · DOI
- Kishida, 2012, Increase in covalent binding of 5-hydroxydiclofenac to hepatic tissues in rats co-treated with lipopolysaccharide and diclofenac: involvement in the onset of diclofenac-induced idiosyncratic hepatotoxicity, J. Toxicol. Sci., 37, 1143, 10.2131/jts.37.1143 · DOI
- Van Zyl, 1979, The influence of non-steroidal anti-inflammatory and antithyroid agents on myeloperoxidase-catalysed activities of human leucocytes, South Afr. Med. J., 55, 1082
- Chatterjee, 1993, Inhibition of intestinal peroxidase activity by nonsteroidal antiinflammatory drugs, Biochim. Biophys. Acta, 1161, 168, 10.1016/0167-4838(93)90210-I · doi:10.1016/0167-4838(93)90210-i
- Singh, 2009, Binding modes of aromatic ligands to mammalian heme peroxidases with associated functional implications: crystal structures of lactoperoxidase complexes with acetylsalicylic acid, salicylhydroxamic acid, and benzylhydroxamic acid, J. Biol. Chem., 284, 20311, 10.1074/jbc.M109.010280 · DOI
- Foss, 2005, The pathway by which the tetrameric protein transthyretin dissociates, Biochemistry, 44, 15525, 10.1021/bi051608t · DOI · Paper page
- Andrade, 1952, A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves, Brain J. Neurol., 75, 408, 10.1093/brain/75.3.408 · DOI · Paper page
- Coelho, 1996, Familial amyloid polyneuropathy: new developments in genetics and treatment, Curr. Opin. Neurol., 9, 355, 10.1097/00019052-199610000-00007 · DOI · Paper page
- Jacobson, 1997, Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans, N. Engl. J. Med., 336, 466, 10.1056/NEJM199702133360703 · DOI · Paper page
- Westermark, 1990, Fibril in senile systemic amyloidosis is derived from normal transthyretin, Proc. Natl. Acad. Sci. U. S. A., 87, 2843, 10.1073/pnas.87.7.2843 · DOI · Paper page
- Klabunde, 2000, Rational design of potent human transthyretin amyloid disease inhibitors, Nat. Struct. Biol., 7, 312, 10.1038/74082 · DOI
- Mir, 2009, The structural basis for the prevention of nonsteroidal antiinflammatory drug-induced gastrointestinal tract damage by the C-lobe of bovine colostrum lactoferrin, Biophys. J., 97, 3178, 10.1016/j.bpj.2009.09.030 · DOI
- Troost, 2003, Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers, Eur. J. Clin. Nutr., 57, 1579, 10.1038/sj.ejcn.1601727 · DOI
- Yang, 2007, Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin, J. Struct. Biol., 157, 348, 10.1016/j.jsb.2006.08.015 · DOI · Paper page
- Evans, 2004, PPARs and the complex journey to obesity, Nat. Med., 10, 355, 10.1038/nm1025 · DOI · Paper page
- Lehrke, 2005, The many faces of PPARgamma, Cell, 123, 993, 10.1016/j.cell.2005.11.026 · DOI · Paper page
- McKenna, 2009, Minireview: evolution of NURSA, the nuclear receptor signaling atlas, Mol. Endocrinol., 23, 740, 10.1210/me.2009-0135 · DOI · Paper page
- Hamblin, 2009, PPARs and the cardiovascular system, Antioxid. Redox Signal., 11, 1415, 10.1089/ars.2008.2280 · DOI · Paper page
- Li, 2008, Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties, Diabetes Obes. Metab., 10, 10, 10.1111/j.1463-1326.2007.00708.x · DOI · Paper page
- Waki, 2007, The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression, Cell Metab., 5, 357, 10.1016/j.cmet.2007.03.010 · DOI · Paper page
- Walczak, 2002, PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism, J. Lipid Res., 43, 177, 10.1016/S0022-2275(20)30159-0 · DOI · Paper page
- Waku, 2010, The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites, EMBO J., 29, 3395, 10.1038/emboj.2010.197 · DOI · Paper page
- Owen, 2000, The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p, EMBO J., 19, 6141, 10.1093/emboj/19.22.6141 · DOI · Paper page
- Zeng, 2002, Bromodomain: an acetyl-lysine binding domain, FEBS Lett., 513, 124, 10.1016/S0014-5793(01)03309-9 · DOI · Paper page
- Beck, 1992, A homologue of the Drosophila female sterile homeotic (fsh) gene in the class II region of the human MHC, J. DNA Seq. Mapp., 2, 203, 10.3109/10425179209020804 · DOI · Paper page
- Chung, 2012, Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery, J. Med. Chem., 55, 576, 10.1021/jm201320w · DOI · Paper page
- Gosmini, 2014, The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor, J. Med. Chem., 57, 8111, 10.1021/jm5010539 · DOI · Paper page
- Ciolino, 2006, Sulindac regulates the aryl hydrocarbon receptor-mediated expression of phase 1 metabolic enzymes in vivo and in vitro, Carcinogenesis, 27, 1586, 10.1093/carcin/bgi359 · DOI
- Hu, 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro, Mol. Pharmacol., 71, 1475, 10.1124/mol.106.032748 · DOI · Paper page
- Abdelrahim, 2006, Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation, J. Natl. Cancer Inst., 98, 855, 10.1093/jnci/djj232 · DOI · Paper page
- Abdelrahim, 2004, Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells, Cancer Res., 64, 6740, 10.1158/0008-5472.CAN-04-0713 · DOI · Paper page
- Abdelrahim, 2005, Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins, Mol. Pharmacol., 68, 317, 10.1124/mol.105.011825 · DOI
- Pathi, 2014, Tolfenamic acid inhibits colon cancer cell and tumor growth and induces degradation of specificity protein (Sp) transcription factors, Mol. Carcinog., 53, E53
- Imbimbo, 2010, Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment?, Front. Aging Neurosci., 2
- Perrone, 2015, Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: preliminary investigation, Pharmacology, 95, 22, 10.1159/000369826 · DOI
- Lu, 2015, FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach, Sci. Rep., 5, 8114, 10.1038/srep08114 · DOI
- Joo, 2014, Screening of non-steroidal anti-inflammatory drugs for inhibitory effects on the activities of six UDP-glucuronosyltransferases (UGT1A1, 1A3, 1A4, 1A6, 1A9 and 2B7) using LC–MS/MS, Biopharm. Drug Dispos.
- Frolov, 2012, Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791, PLOS ONE, 7, e38759, 10.1371/journal.pone.0038759 · doi:10.1371/journal.pone.0038759
- Martelli, 2013, Pharmacol. Res., 78, 1, 10.1016/j.phrs.2013.09.008 · DOI
- Eren, 2010, Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors, Bioorg. Med. Chem., 18, 6367, 10.1016/j.bmc.2010.07.009 · DOI
- Tietz, 2013, Synthesis of three 18F-labelled cyclooxygenase-2 (COX-2) inhibitors based on a pyrimidine scaffold, Org. Biomol. Chem., 11, 8052, 10.1039/c3ob41935e · DOI
- Consalvi, 2015, Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors, Bioorg. Med. Chem., 23, 810, 10.1016/j.bmc.2014.12.041 · doi:10.1016/j.bmc.2014.12.041
- Gupta, 2004, Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors, Bioorg. Med. Chem. Lett., 14, 667, 10.1016/j.bmcl.2003.11.034 · doi:10.1016/j.bmcl.2003.11.034
- Chan, 1999, Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther., 290, 551, 10.1016/S0022-3565(24)34934-1 · DOI · Paper page
- Viegas, 2011, Binding of ibuprofen, ketorolac, and diclofenac to COX-1 and COX-2 studied by saturation transfer difference NMR, J. Med. Chem., 54, 8555, 10.1021/jm201090k · doi:10.1021/jm201090k
- Riendeau, 2001, Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2, J. Pharmacol. Exp. Ther., 296, 558, 10.1016/S0022-3565(24)38776-2 · DOI · Paper page
- Warner, 1999, Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci. U. S. A., 96, 7563, 10.1073/pnas.96.13.7563 · DOI · Paper page
- Wester, 2003, Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1Å resolution: evidence for an induced fit model of substrate binding, Biochemistry, 42, 9335, 10.1021/bi034556l · DOI · Paper page
- Milojevic, 2009, Human serum albumin inhibits Abeta fibrillization through a monomer-competitor mechanism, Biophys. J., 97, 2585, 10.1016/j.bpj.2009.08.028 · DOI
- Desfosses, 1991, Ligand binding at membrane mimetic interfaces. Human serum albumin in reverse micelles, Eur. J. Biochem. FEBS, 199, 79, 10.1111/j.1432-1033.1991.tb16094.x · doi:10.1111/j.1432-1033.1991.tb16094.x
- Honoré, 1983, Interaction of indomethacin with adult human albumin and neonatal serum, Dev. Pharmacol. Ther., 6, 347, 10.1159/000457335 · doi:10.1159/000457335
Cited by
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Dwivedi, A. K., Gurjar, V., Kumar, S., & Singh, N.
- ORCID
- Singh, Nagendra
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 20
- Issue
- 7
- Pages
- 863-873
- ISSN
- 1359-6446
- Cited by
- 61
- References
- 5
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- ICMR
- DST
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.